Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine [Seeking Alpha]
Keros Therapeutics, Inc. - common stock (KROS)
Company Research
Source: Seeking Alpha
Despite a strong cash position and a Takeda partnership elsewhere, the future of Keros' lead candidate, Cibotercept, appears bleak. The company has a cash runway of 13 quarters, but high short interest and low trading volume pose additional risks. Given the current situation, I recommend avoiding KROS, although risk-loving investors might find its low price and cash reserves appealing. I covered Keros Therapeutics, Inc. ( NASDAQ: KROS early last year, and once in the year before that. The stock is down 70+% from those times. The stock was actually trading about 50% up from my coverage price of that About the TPT service Thanks for reading. At the Total Pharma Tracker , we offer the following:- Our Android app and website features a set of t
Read more
Impact Snapshot
Event Time:
KROS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KROS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KROS alerts
High impacting Keros Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
KROS
News
- Keros Therapeutics, Inc. (NASDAQ: KROS) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.MarketBeat
- Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy VolunteersGlobeNewswire
- Keros Therapeutics Announces Participation at Upcoming Healthcare ConferencesGlobeNewswire
KROS
Earnings
- 2/26/25 - Miss
KROS
Sec Filings
- 3/31/25 - Form 8-K
- 3/6/25 - Form 8-K
- 2/28/25 - Form 8-K
- KROS's page on the SEC website